<div>
  <ul>
    <li>
      <p>
        Hartwig Medical Foundation and Ultima Genomics are partnering to deploy Ultima's UG 100 sequencing system and its proprietary ppmSeq technology, aiming to improve precision oncology testing and research.
      </p>
    </li>
    <li>
      <p>
        The partnership's goal is to make genome-based cancer diagnostics more accessible by lowering test costs and providing more precise and comprehensive cancer treatment options. The collaboration will allow Hartwig to use the UG 100 and ppmSeq technology for whole genome tumor profiling and minimal residual disease testing, and the data will be made available to improve the care of future cancer patients.
      </p>
    </li>
    <li>
      <p>
        <b>Analyst QuickTake:&nbsp;</b>
        Ultima introduced
        <a href="https://www.businesswire.com/news/home/20240205026783/en/Ultima-Genomics-to-Launch-UG-100%E2%84%A2-System-and-Present-Data-at-AGBT">
           the UG 100TM system
        </a>
         in February 2024, and it is claimed that it uses a novel sequencing design, offering sequencing at notably 
        <a href="https://www.businesswire.com/news/home/20240206310974/en/Ultima-Announces-UG-100%E2%84%A2-and-Reveals-Disruptive-Cost-and-Accuracy-Profile-to-Enable-the-Era-of-the-100-Genome-and-Beyond">
          reduced costs compared to traditional methods
        </a>
        . Additionally, its ppmSeqTM, an exclusive technology integrated into the UG 100TM platform, is 
        <a href="https://www.businesswire.com/news/home/20240408011173/en/Hartwig-and-Ultima-Genomics-Collaborate-to-Reduce-Costs-for-Whole-Genome-Cancer-Profiling-Minimal-Residual-Disease-Testing-and-Generating-Genetic-Data-at-Scale">
          claimed
        </a>
         to enable ultra-high accuracy at part-per-million levels (Q60) for detecting single nucleotide variants (SNVs).
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20240408011173/en/Hartwig-and-Ultima-Genomics-Collaborate-to-Reduce-Costs-for-Whole-Genome-Cancer-Profiling-Minimal-Residual-Disease-Testing-and-Generating-Genetic-Data-at-Scale">
      <b>Press release</b>
    </a>
  </p>
</div>


Precision Medicine

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>Hartwig Medical Foundation has entered into a partnership with Ultima Genomics to utilize their UG 100 sequencing system and ppmSeq technology. The objective is to enhance precision oncology testing and research.</p>
 <p>This collaboration is aimed at making genome-based cancer diagnostics more accessible by reducing testing costs, while providing higher precision and comprehensive cancer treatment choices. Hartwig gets to use the UG 100 and ppmSeq technology for comprehensive genome profiling of tumors and minimal residual disease testing. The generated data will be utilized to improve future cancer patient care.</p>
</div> <p><b>Analyst QuickTake:<br>
&nbsp;</b> Ultima introduced <a href="https:<br>
//www.businesswire.com/news/home/20240205026783/en/Ultima-Genomics-to-Launch-UG-100%E2%84%A2-System-and-Present-Data-at-AGBT"> the UG 100TM system </a> in February 2024, and it is claimed that it uses a novel sequencing design, offering sequencing at notably <a href="https:<br>
//www.businesswire.com/news/home/20240206310974/en/Ultima-Announces-UG-100%E2%84%A2-and-Reveals-Disruptive-Cost-and-Accuracy-Profile-to-Enable-the-Era-of-the-100-Genome-and-Beyond"> reduced costs compared to traditional methods </a> . Additionally, its ppmSeqTM, an exclusive technology integrated into the UG 100TM platform, is <a href="https:<br>
//www.businesswire.com/news/home/20240408011173/en/Hartwig-and-Ultima-Genomics-Collaborate-to-Reduce-Costs-for-Whole-Genome-Cancer-Profiling-Minimal-Residual-Disease-Testing-and-Generating-Genetic-Data-at-Scale"> claimed </a> to enable ultra-high accuracy at part-per-million levels (Q60) for detecting single nucleotide variants (SNVs).</p>

All Updates

Ultima Genomics partners with Hartwig Medical Foundation to improve precision oncology testing and research

Ultima Genomics and Genome Insight to bring low-cost whole-genome sequencing to cancer patients